Our research group is part of the Consorcio Centro de Investigación Biomédica en Red (CIBER) since its creation in 2007, specifically in the area of Bioengineering, Biomaterials and Nanomedicine area, with the code CB06-01-0010, a group lead by Prof. Carles Arús since this creation and until November 2024, when Dr. Ana Paula Candiota has assumed the leadership. This group has accounted with stable senior researchers such as Margarida Julià (period 2007-2021) and Ana Paula Candiota (period 2007-2023), besides different members from clinical, basic research and bioinformatic environments. The group is also in charge of Unit 25 of ICTS NANBIOSIS.
Objectives and thematic areas
The objective of CIBER, created through an initiative of Instituto de Salud Carlos III (ISCIII), is to boost the research of excellence in Biomedicine and Health Sciences. In order to achieve this aim, multi-institutional and interdisciplinar resources and efforts are focused with a preferent dedication to knowledge networks formed by centers and research groups from public and private institutions. The corporative video below offers a summary of the CIBER initiative.
The origen of CIBER traces back to 2006 when 7 of the consortia were created (CIBERBBN, CIBEREHD, CIBERBNED, CIBERER, CIBERES, CIBERESP y CIBEROBN). In 2007 two further consortiums were created, CIBERSAM y CIBERDEM. In 2013, with effects to 1 January 2014, in the frame of Plan de reestructuración y racionalización del Sector Público, the integraton of CIBER-BBN, CIBEREHD, CIBERER, CIBERES, CIBERESP, CIBEROBN, CIBERDEM y CIBERSAM in a single Consortium named Consorcio denominado Consorcio Centro de Investigación Biomédica en Red, CIBER, was approved. In 1 January 2017, within the call Acción Estratégica en Salud 2013-2016, new thematic areas and groups were incorporated to the Consorcio CIBER. The new thematic areas were the following: Fragilidad y Envejecimiento Saludable (CIBERFES), Enfermedades Cardiovasculares (CIBERCV) and Cáncer (CIBERONC). Finally, in January 2022 the process of new thematic areas integration finished with the creation of CIBER de Enfermedades Infecciones (CIBERINFEC) and the incorporation of CIBER de Enfermedades Neurodegenerativas (CIBERNED).
Present
Presently, the CIBER has a staff of 831 people and 5.654 ascribed researchers, integrated into 518 research groups, without physical association, and linked to 104 institucions belonging to administration and institution from the public and private sectors of different autonomous communities.
The scientific programme of CIBER is structured around the following research areas:
- Bioingeniería, Biomateriales y Nanomedicina (CIBER-BBN)
- Diabetes y Enfermedades Metabólicas (CIBERDEM)
- Fisiopatología de la Obesidad y Nutrición (CIBEROBN)
- Enfermedades Hepáticas y Digestivas (CIBEREHD)
- Enfermedades Raras (CIBERER)
- Enfermedades Respiratorias (CIBERES)
- Epidemiología y Salud Pública (CIBERESP)
- Salud Mental (CIBERSAM)
- Fragilidad y Envejecimiento Saludable (CIBERFES)
- Enfermedades Cardiovasculares (CIBERCV)
- Cáncer (CIBERONC)
- Enfermedades Infecciosas (CIBERINFEC)
- Enfermedades Neurodegenerativas (CIBERNED)
